Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
EVIVE Biotechnology
Study Stage: Phase III Study Population: Female patients with breast cancer will be enrolled to receive at least 4 cycles of Epirubicin + Cyclophosphamide (EC) chemotherapy, that is: epirubicin 100 mg/m\^2 and cyclophosphamide 600 mg/m\^2. Study Design: A multi-center, randomized, open-label, active-controlled phase III clinical trial
Age
18–75
Sex
FEMALE
Healthy volunteers
Not accepted